Business Context and Reporting Period
This Form 8-K, dated April 28, 2025, reports on an amendment to the Merger Agreement between GlycoMimetics, Inc. (the registrant) and Crescent Biopharma, Inc. The filing details the entry into a material definitive agreement to modify the terms of the proposed business combination originally dated October 28, 2024.
Key Financial Metrics and Transaction Terms
- Exchange Ratio: Based on capitalization as of April 15, 2025, each share of Crescent common stock is estimated to receive approximately 15.4192 shares of GlycoMimetics common stock.
- Post-Merger Ownership: Existing GlycoMimetics securityholders are expected to own approximately 2.6% of the combined company on a fully-diluted basis. Former Crescent securityholders are expected to own approximately 97.4%.
- Cash Position Assumption: The ownership percentages assume GlycoMimetics' net cash at closing equals $1.8 million.
- RSU Treatment: Crescent restricted stock units (RSUs) will be assumed by GlycoMimetics using the same exchange ratio applied to other Crescent securities.
Material Changes and Agreement Amendments
The Amendment to the Merger Agreement introduces two primary changes:
- Establishment of the assumption of Crescent RSUs by GlycoMimetics upon merger completion.
- Clarification of voting mechanics regarding the Certificate of Designation of Preferences, Rights and Limitations of the Series A Non-Voting Convertible Preferred Stock to be filed by GlycoMimetics.
Outlook, Risks, and Management Commentary
Regulatory Status: The SEC and state securities commissions have not approved or disapproved of the securities or determined if this report is truthful or complete. The filing is not a solicitation of a proxy or an offer to sell securities.
Investor Action: Management urges investors to read the Registration Statement on Form S-4 and other relevant documents filed with the SEC for comprehensive information regarding the transaction, risks, and related matters.
Contingencies: The transaction is subject to regulatory approvals and the assumption that GlycoMimetics' net cash at closing remains at $1.8 million. Ownership percentages are subject to dilution from equity issued by Crescent after April 15, 2025, and before closing.
Key Facts for Investor Verification
- Verify the final exchange ratio of 15.4192 shares of GlycoMimetics stock per Crescent share in the definitive Form S-4.
- Confirm the actual net cash position of GlycoMimetics at the time of closing to validate the projected 2.6% / 97.4% ownership split.
- Review the full text of the Amendment (Exhibit 10.1) for specific details on the Series A Non-Voting Convertible Preferred Stock voting mechanics.
- Monitor the status of the Form S-4 Registration Statement for updated risk factors and transaction timelines.